Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications

References

• World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017.
   Google Scholar
• Patten SB, Williams JV, Lavorato DH, Modgill G, Jette N, Eliasziw M. Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. Gen Hosp Psychiatry. 2008;30(5):407–413. doi:10.1016/j.genhosppsych.2008.05.00118774423
   PubMed Web of Science ®Google Scholar
• Rotella F, Mannucci E. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry. 2013;74(1):31–37. doi:10.4088/JCP.12r0792223419223
   PubMed Web of Science ®Google Scholar
• Rotermann M, Sanmartin C, Hennessy D, Arthur M. Prescription medication use by Canadians aged 6 to 79. Health Rep. 2014;25(6):3–9.
   Web of Science ®Google Scholar
• Prevention CfDCa. National Ambulatory Medical Care Survey: 2015 State and National Summary Tables. U.S. Department of Health and Human Services Available from: https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2015_namcs_web_tables.pdf. Accessed 712, 2018.
   Google Scholar
• Vasiliadis HM, Lesage A, Adair C, Wang PS, Kessler RC. Do Canada and the United States differ in prevalence of depression and utilization of services? Psychiatr Serv. 2007;58(1):63–71. doi:10.1176/ps.2007.58.1.6317215414
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. doi:10.1177/070674371665941727486148
   PubMed Web of Science ®Google Scholar
• Canada CBo. Healthy Brains at Work: estimating the Impact of Workplace Mental Health Benefits and Programs. Available from: https://www.conferenceboard.ca/e-library/abstract.aspx?did=8242. Accessed 717, 2018.
   Google Scholar
• Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–162. doi:10.4088/JCP.14m0929825742202
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.190517074942
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459. doi:10.1007/s11920-007-0061-318221624
   PubMedGoogle Scholar
• Bousman CA, Jaksa P, Pantelis C. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenet Genomics. 2017;27(11):387–393. doi:10.1097/FPC.0000000000000]30328777243
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. Does Pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017;78(6):720–729. doi:10.4088/JCP.15r1058328068459
   PubMed Web of Science ®Google Scholar
• Bousman CA, Dunlop BW. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J. 2018;18(5):613–622. doi:10.1038/s41397-018-0027-329795409
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. J Affect Disord. 2018;241:484–491. doi:10.1016/j.jad.2018.08.05630149336
   PubMed Web of Science ®Google Scholar
• Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20(1):37–47. doi:10.2217/pgs-2018-014230520364
   PubMed Web of Science ®Google Scholar
• Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23(10):535–548. doi:10.1097/FPC.0b013e3283649b9a24018772
   PubMed Web of Science ®Google Scholar
• Hall-Flavin DK, Winner JG, Allen JD, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012;2:e172.23047243
   PubMed Web of Science ®Google Scholar
• Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013;16(89):219–227.24229738
   PubMed Web of Science ®Google Scholar
• Greden JF, Parikh SV, Rothschild AJ, et al. Combinatorial pharmacogenomic testing improves outcomes in major depression. Am J Psychiatry. 2018 (Submitted).
   Web of Science ®Google Scholar
• Tanner JA, Davies PE, Voudouris NC, et al. Combinatorial pharmacogenomics and improved patient outcomes in depression: treatment by primary care physicians or psychiatrists. J Psychiatr Res. 2018;104:157–162. doi:10.1016/j.jpsychires.2018.07.01230081389
   PubMed Web of Science ®Google Scholar
• Hornberger J, Li Q, Quinn B. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am J Manag Care. 2015;21(6):e357–365.26247576
   PubMed Web of Science ®Google Scholar
• Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:e242. doi:10.1038/tp.2013.223511609
   PubMed Web of Science ®Google Scholar
• Winner JG, Carhart JM, Altar CA, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31(9):1633–1643. doi:10.1185/03007995.2015.106348326086890
   PubMed Web of Science ®Google Scholar
• Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 2017;39(3):592–602.e591. doi:10.1016/j.clinthera.2017.01.02228238356
   PubMed Web of Science ®Google Scholar
• Benitez J, Cool CL, Scotti DJ. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Per Med. 2018;15(6):481–494. doi:10.2217/pme-2018-007430256179
   PubMedGoogle Scholar
• Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada. Ottawa, ON: CIHI2014 2012 [updated 10 2014] Available from: https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC2594. Accessed 712, 2018.
   Google Scholar
• Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med. 2011;26(10):1175–1182. doi:10.1007/s11606-011-1704-y21533823
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. Pharmaceutical spending (indicator); 2018 Available from: https://data.oecd.org/healthres/pharmaceutical-spending.htm. Accessed 712, 2018.
   Google Scholar